PNP30: CHANGES IN QUALITY OF LIFE RESULTING FROM TREATMENT FOR PERSONS WITH ADVANCED PARKINSON'S DISEASE: SUMANIROLE VERSUS PLACEBO  by DuChane, J & Jenkinson, C
282 Abstracts
Correlations of ADAS-Cog and MMSE with category
scores were highest with paranoid/delusions (r = 0.25,
ADAS-Cog; r = -0.16, MMSE) and activity disturbances
(r = 0.25, ADAS-Cog; r = -0.25, MMSE). The weakest
relationships, not statistically signiﬁcant, were found on
aggressiveness (r = 0.01, ADAS-Cog; r = -0.06, MMSE)
and diurnal rhythm (r = -0.12, ADAS-Cog; r = 0.09,
MMSE). CONCLUSIONS: Given the relatively low cor-
relations (r < 0.40) of the BEHAVE-AD-FW with ADAS-
Cog and MMSE, the BEHAVE-AD-FW may measure
previously undetected symptoms of dementia in AD and
might be an independent supplement to measures of 
cognition.
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Russian State Medical University, Moscow, Russia
OBJECTIVES: To assess an inﬂuence of depression,
dementia, disease severity and motor complications on
the Quality of Life (QoL) in Parkinson’s Disease (PD).
METHODS: Quality of Life was measured in 241
patients with PD (male: 127, female: 114, mean age: 66.1
± 7.5, duration of disease: 5.2 ± 3.2) using the Parkinson
Disease Questionnaire (PDQ-39), a disease-speciﬁc
instrument. Dementia was evaluated by using the MMSE
and depression was evaluated by Hamilton Rating Scale
(HAM). Disease severity and motor function were
recorded with the Hoehn and Yahr scale and the UPDRS
II-IV. Spearman’s correlation coefﬁcient was used to 
calculate correlation scores. RESULTS: All domains of
PDQ-39 signiﬁcantlty correlated with depressive symp-
toms. Signiﬁcant correlation between HAM scores and
PDQ-39 summary index (R = 0.53, p < 0.001) was
observed. PDQ-39 also correlated with UPDRS II (R =
0.67, p < 0.001), UPDRS III (R = 0.49, p < 0.001) and
HY stage (R = 0.62, p < 0.001). Motor ﬂuctuations and
dyskinesias (UPDRS IV) had signiﬁcant impact on QoL
(R = 0.57, p < 0.001). Dementia or cognitive impairment
had a minor correlation with UPDRS III and HY stage (R
= -0.32, p < 0.001 and R = -0.44, p < 0.001, respectively)
but had no correlation with PDQ-39. CONCLUSIONS:
Disease severity, motor ﬂuctuations, and depression inﬂu-
ence on QoL in patients with Parkinson’s disease. In 
contrast, a signiﬁcant impact of cognitive impairment on
QoL of patients with Parkinson’s Disease was not
revealed. Treatment of depressive symptoms and preven-
tion of motor complications in PD patients may improve
considerably their Quality of Life.
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CLINITRAC:A NOVEL METHOD FOR
EVALUATING OUTCOME IN PARKINSON
DISEASE
Bingefors K, Isacson D, Kristiansen IS
Uppsala University, Uppsala, Sweden
OBJECTIVES: Parkinson’s Disease (PD) is a chronic neu-
rological disease with disabling motor symptoms such as
tremor and rigidity, which may occur intermittently. The
DIREQT trial is an open label randomised trial designed
to study the effects of Duodopa (intra-intestinal admini-
stration of l-DOPA) compared to conventional oral
therapy of PD. DIREQT has three phases: 1) two weeks
pre-study phase; and 2) two weeks of Duodopa followed
by two weeks of conventional therapy—or vice versa; 
C: 6 months follow-up with conventional therapy or
Duodopa depending on patient preferences. Since PD
symptoms ﬂuctuate from hour to hour, standard methods
for evaluating quality of life are less suitable. The aim of
this paper is to describe a novel method for assessing
outcome in PD. METHODS: The Clinitrac system 
consists of a handheld computer (PDA) with a mobile
telephone. The PDA is pre-programmed with PD ques-
tionnaires (UPDRS, PSAA, PDQ-39) and generic quality
of life (QoL) instruments (TTO, 15D). Patients receive
notiﬁcation to ﬁll in the forms through the PDA at 8 AM,
noon, 4 PM and 8PM. Entries are automatically trans-
mitted to a central database via the mobile phone. If the
patient does not respond within 15 minutes, the data will
be reported missing and later entry is not allowed. The
principal investigator and a research nurse have access 
to the database, supervise the data collection and may
contact patients with high missing rates. RESULTS:
During the period August 2002 through November 2002
in total 12 patients have been included in the study. All
were able to use the PDA in spite of severe PD symptoms.
The rate of compliance with scheduled data entries varied
between 77% and 97%. CONCLUSION: Clinitrac seems
to offer a system that is acceptable to the patient for
repeated QoL measurements during one single day. Com-
pliance with the scheduled data entries is excellent, but
validity of entries has not yet been established.
PNP30
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OBJECTIVE: Parkinson’s disease (PD) has consistently
been shown to exert a negative inﬂuence on patient-
reported quality of life (QoL). Few studies have differen-
tiated between early and advanced disease. A study
focusing on patients with advanced disease was desired
because it is expected that all patients will ultimately
experience an advanced form of PD, and that this infor-
mation would be useful for patients, caregivers, and
health care administrators. The objective of this study
was to assess the impact of sumanirole, a new, highly
selective D2 dopamine receptor agonist, on the QoL of
patients with advanced PD. METHODS: A double-blind,
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randomized, placebo-controlled, parallel-group study
was conducted in 280 patients with advanced PD who
were receiving levodopa. The study included a 7-week
escalation phase, a 4-week maintenance phase, and a 1-
week taper phase. QoL outcomes for the intent-to-treat
groups were evaluated as secondary endpoints within the
clinical trial. These endpoints were assessed through the
use of 3 fully validated QoL instruments: the PD Ques-
tionnaire (PDQ-39), the EuroQol (EQ-5D), and the Func-
tional Status Questionnaire (FSQ). RESULTS: Signiﬁcant
differences in mean change scores favoring sumanirole
were apparent in the domain pertaining to Activities of
Daily Living (ADL) within the PDQ-39 and in the Overall
Summary Score of the PDQ-39 (P < 0.0006 and P <
0.0093, respectively). Signiﬁcant differences favoring
sumanirole were observed in the domain associated with
Usual Activities in the EQ-5D (P < 0.0280) and in the
Basic Activities of Daily Living domain of the FSQ (P <
0.0092). Changes in the Mobility domain in the PDQ-39
also trended toward signiﬁcance in favor of sumanirole
(P < 0.0556). CONCLUSIONS: These data demonstrate
consistent ﬁndings of improved QoL when assessed by
each of three QoL instruments for patients with advanced
PD who were treated with sumanirole.
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Attention deﬁcit hyperactivity disorder (ADHD) is a
behavioral disorder originating in early childhood, with
a high risk for continued symptoms into adolescences and
adulthood. Although stimulant medications are often 
recommended to treat ADHD, parents’ views of these
medications have not been reported in the literature.
OBJECTIVES: To report pilot study results of a ques-
tionnaire developed to evaluate parent perceptions of
medications to treat ADHD symptoms in children.
METHODS: A parent questionnaire (Parent Perceptions
of Medication for ADHD Questionnaire) was adapted
from previously developed physician perception survey.
Prior to administration, two physicians experienced in
treating ADHD children reviewed the parent question-
naire for face validity. Item responses were either yes/no
questions or rated on a 6-point scale. Face-to-face inter-
viewer administered follow-up questions were performed
to assess questionnaire clarity and relevance. The study
subjects were recruited from a sample of parents who had
an ADHD child enrolled in a Midwestern ADHD clinic.
RESULTS: Forty-three parents of children with ADHD
participated in the study. The Flesch-Kincaid grade level
readability of the questionnaire was 3.7. A majority
(95%) of parents indicated they understood the classiﬁ-
cation of medications as a stimulant or a controlled sub-
stance however, many of the parents were not able to cor-
rectly deﬁne these terms. When deciding whether or not
to have their child take medication for ADHD, 54% and
61% stated that their decision was not inﬂuenced by
whether the medication was a stimulant or controlled
substance, respectively. A majority of the parents sur-
veyed indicated that they were concerned about their
child taking a stimulant (58%) and would prefer a non-
stimulant option if approved by the FDA (79%). CON-
CLUSIONS: Although parents reported the questionnaire
was clear and understandable, many were not able to
deﬁne key terms. With this questionnaire it was possible
to quantify parent’s perceptions towards ADHD drug
treatment.
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OBJECTIVES: To study the inﬂuence of different factors
on QOL of patients with partial epilepsy. METHODS:
Frequency, severity (NHS3 scale, M. F. O’Donoghue et
al., 1996) of seizures and QOL (QOLIE-31 scale, J.
Cramer 1998) were analyzed in the population of 242
adult epilepsy patients with partial epilepsy in Moscow.
The cross-cultural adaptation of the QOLIE-31 scale was
performed. RESULTS: Patients with partial epilepsy 
who experienced persistent seizures and received ineffec-
tive antiepileptic medication had signiﬁcantly lower total
QOL scores than patients receiving optimized therapy:
42.13 ± 4.14 and 48.89 ± 5.45, respectively (ð < 0.001).
The QOL of patients with partial epilepsy depends on 
the duration of the disease and severity and frequency 
of seizures. The severity of seizures has the strongest 
correlation with subscales of emotional well-being,
energy/fatigue, medication effects, and social functioning,
whereas the frequency of seizures had the strongest 
correlation with seizure worry, energy/fatigue, cognitive
functioning, and social functioning. After optimized
therapy 59% of patients became seizure-free. The QOL
of patients receiving optimized therapy depends on their
response to the antiepileptic medication. Seizure-free were
characterized by improvement in all subscales of QOLIE-
31, with a total score of 52.71 ± 3.41. Clinical efﬁ-
cacy/tolerability, QOL improvement, cost-effectiveness
parameters were similar on carbamazepine or valproate
monotherapy, that supports the use of valproate as ade-
quate ﬁrst-line drugs in patients with partial epilepsy.
Even one or two persistent seizures per year signiﬁcantly
decreased the patient’s QOL in comparison to seizure-free
patients. CONCLUSIONS: The quality of life of patients
with partial epilepsy depends on the duration of the
disease and severity and frequency of seizures. Long-term
ineffective therapy caused a negative effect on QOL.
